[1] 中华医学会眼科学会眼底病学组.我国糖尿病视网膜病变临床诊 疗指南(2014年).中华眼科杂志,2014,50(11):851-865. [2] 刘旭,王霞,何媛.糖尿病视网膜病变危险因素与预防研究进展[J]. 眼科新进展,2018,38(7):687-691. [3] 张丽红,王强,孟宇,等.23G微创玻切联合康柏西普眼内注射在增 殖性糖尿病视网膜病变治疗中的应用[J].中国医药指南,2018,16 (26):94-95. [4] Thounaojam MC, Powell FL, Patel S,et al. Protective effects of agonists of growth hormone- releasing hormone (GHRH) in early experimental diabetic retinopathy [J]. Proc Natl Acad Sci USA,2017,114(50):13248-13253. [5] Mohan N, Monickaraj F, Balasubramanyam M,et al. Im-balanced levels of angiogenic and angiostatic factors in vit-reous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy [J]. J Diabetes Com-plicat,2012,26(5):435-441. [6] Wei YM, Yan J, Yang HX. Identification of severe gesta-tional diabetes mellitus after new criteria used in China [J]. Perinatol,2016,36(2):90-94. [7] 薛鹏程,游志鹏,付书华,等.23G玻璃体切割术前、术中辅助玻璃 体内注射康柏西普治疗增生型糖尿病视网膜病变(PDR)的疗效 分析[J].眼科新进展,2017,37(5):458-462. [8] 马锋伟,杜翠云,程美红,等.康柏西普与曲安奈德玻璃体腔注射 治疗视网膜中央静脉阻塞继发黄斑水肿临床疗效的比较[J].中华 实验眼科杂志,2016,34(9):837-841.